FrancophonIA/ELRC3.0 huggingface dataset:
English: While similar blood pressure was achieved in all treatment groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the endpoint of overt proteinuria, demonstrating a 70% relative risk reduction versus placebo (p = 0.0004) for the higher dose.
Croatian: Dok je sličan krvni tlak postignut u svim ispitivanim skupinama, manje bolesnika u skupini koja je primala 300 mg irbesartana (5,2%) dostiglo je ishod manifestne proteinurije u odnosu na skupinu koja je primala placebo (14,9%) ili na skupinu koja je primala 150 mg irbesartana (9,7%), pokazujući smanjenje relativnog rizika za 70% pri primjeni veće doze u odnosu na placebo (p=0,0004).
English: When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).
Croatian: Ako se utvrdi trudnoća, treba odmah prekinuti terapiju antagonistima receptora angiotenzina II te treba, ako je to primjereno, započeti s alternativnom terapijom (vidjeti dijelove 4.3 i 4.6).
English: Metabolism and nutrition disorders: Not known:
Croatian: Poremećaji metabolizma i prehrane: Nepoznato:
English: As with similar medicines, rare cases of allergic skin reactions (rash, urticaria), as well as localised swelling of the face, lips and/or tongue have been reported in patients taking irbesartan.
Croatian: Kao i kod sličnih lijekova, u bolesnika koji su uzimali irbesartan zabilježeni su rijetki slučajevi alergijskih kožnih reakcija (osip, urtikarija), kao i lokalizirano oticanje lica, usana i/ili jezika.
English: Experience in adults exposed to doses of up to 900 mg/day for 8 weeks revealed no toxicity.
Croatian: Iskustvo je pokazalo da nije bilo toksičnog djelovanja u odraslih ljudi koji su bili izloženi dozama do 900 mg/dan tijekom 8 tjedana.
English: Once daily dosing with 150 mg produced trough and mean 24 hour responses similar to twice daily dosing on the same total dose.
Croatian: Jednokratno dnevno doziranje od 150 mg tijekom 24 sata pokazuje najnižu i srednju vrijednost terapijskog odgovora sličnu doziranju iste ukupne doze dva puta na dan.
English: As with other medicinal products that affect the renin-angiotensin-aldosterone system, hyperkalemia may occur during the treatment with Ifirmasta, especially in the presence of renal impairment, overt proteinuria due to diabetic renal disease, and/or heart failure.
Croatian: Kao i kod ostalih lijekova koji djeluju na renin-angiotenzin-aldosteronski sustav, tijekom liječenja Ifirmastom može se pojaviti hiperkalijemija, posebice ako je prisutna i oštećena bubrežna funkcija, izražena proteinurija zbog dijabetičke bubrežne bolesti i/ili zatajenje srca.
English: In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/day and serum creatinine ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of irbesartan on the progression of renal disease and all-cause mortality were examined.
Croatian: U 1715 hipertenzivnih bolesnika sa šećernom bolešću tipa 2, proteinurijom ≥900 mg/dan i serumskim kreatininom u rasponu od 1,0 do 3,0 mg/dl ispitivan je dugotrajan učinak irbesartana (srednja vrijednost 2,6 godina) na progresiju bubrežne bolesti i svih uzroka mortaliteta.
English: - Very common (may affect more than 1 in 10 people): if you suffer from high blood pressure and type 2 diabetes with kidney disease, blood tests may show an increased level of potassium.
Croatian: - Vrlo često (mogu se javiti u više od 1 na 10 osoba): ako imate visoki krvni tlak i šećernu bolest tipa 2 te bolest bubrega, krvne pretrage mogu pokazati povišene vrijednosti kalija.
English: In diabetic hypertensive patients with microalbuminuria and normal renal function, orthostatic dizziness and orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon) but in excess of placebo.
Croatian: U bolesnika koji boluju od hipertenzije i šećerne bolesti s mikroalbuminurijom, uz normalnu bubrežnu funkciju, prijavljene su ortostatska omaglica i ortostatska hipotenzija kod njih 0,5% (tj. manje često), ali s većom učestalošću nego kod placeba.
English: Adjusted mean change of trough seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium dose), 5.6 mmHg (high dose).
Croatian: Prilagođena srednja vrijednost promjene dijastoličkog krvnog tlaka u sjedećem položaju u «najnižoj točki djelovanja» (engl. seated diastolic blood pressure, SeDBP) bila je sljedeća: 3,8 mmHg (niska doza), 3,2 mmHg (srednja doza) i 5,6 mmHg (visoka doza).
English: Some undesirable effects have been reported since marketing of irbesartan.
Croatian: Neke nuspojave prijavljene su otkad je irbesartan na tržištu.
English: However, occasionally dizziness or weariness may occur during treatment of high blood pressure.
Croatian: Međutim, za vrijeme liječenja visokog krvnog tlaka povremeno se mogu pojaviti omaglica ili iznurenost.
English: There is no clinical experience in patients with severe hepatic impairment.
Croatian: Nema kliničkog iskustva s bolesnicima s teškim oštećenjem funkcije jetre.
English: 14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 56 film-coated tablets 56x1 film-coated tablets 84 film-coated tablets 90 film-coated tablets 98 film-coated tablets
Croatian: 14 filmom obloženih tableta 28 filmom obloženih tableta 30 filmom obloženih tableta 56 filmom obloženih tableta 56x1 filmom obloženih tableta 84 filmom obložene tablete 90 filmom obloženih tableta 98 filmom obloženih tableta
English: How to store Ifirmasta
Croatian: Kako čuvati Ifirmastu
English: Side effects reported in clinical studies for patients treated with irbesartan were:
Croatian: U kliničkim ispitivanjima na bolesnicima liječenima irbesartanom prijavljene su sljedeće nuspojave:
English: Ifirmasta is used in adult patients - to treat high blood pressure (essential hypertension) - to protect the kidney in patients with high blood pressure, type 2 diabetes and laboratory evidence of impaired kidney function.
Croatian: Ifirmasta se primjenjuje u odraslih bolesnika za - liječenje visokog krvnog tlaka (esencijalne hipertenzije), - zaštitu bubrega u bolesnika sa šećernom bolešću tipa 2 koji imaju povišeni krvni tlak i laboratorijski dokazanu oslabljenu bubrežnu funkciju.
English: - Common (may affect up to 1 in 10 people): dizziness, feeling sick/vomiting, and fatigue and blood tests may show raised levels of an enzyme that measures the muscle and heart function (creatine kinase enzyme).
Croatian: - Često (mogu se javiti u manje od 1 na 10 osoba): omaglica, mučnina/povraćanje i umor; krvne pretrage mogu pokazati povišene razine enzima specifičnog za mišićnu i srčanu funkciju (enzim kreatin kinaza).
English: Immune system disorders: Not known:
Croatian: Poremećaji imunološkog sustava: Nepoznato:
English: In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease.
Croatian: U hipertenzivnih bolesnika sa šećernom bolešću tipa 2, liječenje treba započeti sa 150 mg irbesartana jedanput na dan i dozu titrirati do 300 mg jedanput na dan, što je doza održavanja koja se preporučuje za liječenje bubrežne bolesti.
English: A lower starting dose (75 mg) should be considered for patients undergoing haemodialysis (see section 4.4).
Croatian: U bolesnika na hemodijalizi treba razmotriti započinjanje liječenja nižom početnom dozom (75 mg) (vidjeti dio 4.4).
English: In diabetic hypertensive patients with microalbuminuria and normal renal function, hyperkalaemia (≥ 5.5 mEq/L) occurred in 29.4% of the patients in the irbesartan 300 mg group and 22% of the patients in the placebo group.
Croatian: U bolesnika sa šećernom bolešću i hipertenzijom, mikroalbuminurijom i normalnom bubrežnom funkcijom, hiperkalijemija (≥ 5,5 mEq/L) se razvila kod 29,4% bolesnika koji su primali 300 mg irbesartana i kod 22% bolesnika u placebo skupini.
English: Sixty per cent (60%) of patients in the placebo group reached this target blood pressure whereas this figure was 76% and 78% in the irbesartan and amlodipine groups respectively.
Croatian: U skupini koja je primala placebo, 60% bolesnika postiglo je ciljni krvni tlak dok je ta vrijednost bila 76% u skupini koja je primala irbesartan, odnosno 78% u skupini koja je primala amlodipin.
English: Skin and subcutaneous tissue disorders: Not known:
Croatian: Poremećaji kože i potkožnog tkiva: Nepoznato:
English: Ifirmasta slows the decrease of kidney function in patients with high blood pressure and type 2 diabetes.
Croatian: Ifirmasta usporava slabljenje bubrežne funkcije u bolesnika koji imaju povišen krvni tlak i boluju od šećerne bolesti tipa 2.
English: Ear and labyrinth disorder: Not known:
Croatian: Poremećaji uha i labirinta: Nepoznato:
English: At the end of the three weeks the mean reduction from baseline in the primary efficacy variable, trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose), 13.2 mmHg (high dose).
Croatian: Nakon tri tjedna srednja vrijednost smanjenja krvnog tlaka u odnosu na početne vrijednosti za primarnu varijablu djelotvornosti, sistolički krvni tlak u sjedećem položaju kod najniže koncentracije u krvi (engl. seated systolic blood pressure, SeSBP), iznosila je 11,7 mmHg (niska doza), 9,3 mmHg (srednja doza) i 13,2 mmHg (visoka doza).
English: The demonstration of renal benefit of Ifirmasta in hypertensive type 2 diabetic patients is based on studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).
Croatian: Dokaz koristi Ifirmaste na bubrežnu funkciju u hipertenzivnih bolesnika sa šećernom bolešću tipa 2 zasniva se na ispitivanjima u kojima se irbesartan prema potrebi uzimao kao dopuna ostaloj antihipertenzivnoj terapiji za postizanje ciljnog krvnog tlaka (vidjeti dijelove 4.3, 4.4, 4.5 i 5.1).
English: Other antihypertensive agents may increase the hypotensive effects of irbesartan; however Ifirmasta has been safely administered with other antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide diuretics.
Croatian: Ifirmasta se, međutim, pokazala sigurnom za primjenu s ostalim antihipertenzivnim lijekovima poput beta blokatora, dugodjelujućih blokatora kalcijevih kanala i tiazida.
English: In diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria, hyperkalaemia (≥ 5.5 mEq/L) occurred in 46.3% of the patients in the irbesartan group and 26.3% of the patients in the placebo group.
Croatian: U bolesnika sa šećernom bolešću i hipertenzijom s kroničnom bubrežnom insuficijencijom i manifestnom proteinurijom, hiperkalijemija (≥ 5,5 mEq/l) se razvila u 46,3% bolesnika koji su primali irbesartan te u 26,3% bolesnika u placebo skupini.
English: C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces.
Croatian: Nakon peroralne ili i.v. primjene C irbesartana, oko 20% radioaktivnosti pojavilo se u mokraći, a ostatak u stolici.
English: Ifirmasta 75 mg film-coated tablets Ifirmasta 150 mg film-coated tablets Ifirmasta 300 mg film-coated tablets
Croatian: Ifirmasta 75 mg filmom obložene tablete Ifirmasta 150 mg filmom obložene tablete Ifirmasta 300 mg filmom obložene tablete
English: The “Irbesartan Diabetic Nephropathy Trial (IDNT)” shows that irbesartan decreases the progression of renal disease in patients with chronic renal insufficiency and overt proteinuria.
Croatian: Klinička studija «Ispitivanje irbesartana u bolesnika s dijabetičkom nefropatijom« (Irbesartan Diabetic Nephropathy Trial, IDNT) pokazuje da irbesartan smanjuje progresiju bubrežne bolesti u bolesnika s kroničnom bubrežnom insuficijencijom i manifestnom proteinurijom.
English: The study examined the long-term effects (2 years) of irbesartan on the progression to clinical (overt) proteinuria (urinary albumin excretion rate (UAER) > 300 mg/day, and an increase in UAER of at least 30% from baseline).
Croatian: U studiji su ispitivani dugotrajni učinci (2 godine) irbesartana na progresiju klinički izražene proteinurije (brzina izlučivanja albumina u mokraću (engl. urinary albumin excretion rate, UAER)
English: Cardiac disorders: Uncommon: tachycardia
Croatian: Srčani poremećaji: Manje često: tahikardija
English: Ifirmasta is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Croatian: Ifirmasta se ne preporučuje u ranoj trudnoći te se ne smije uzimati nakon trećeg mjeseca trudnoće, jer može ozbiljno naškoditi Vašem djetetu, uzimate li ga u tom razdoblju.
English: Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.
Croatian: Ako je došlo do izloženosti antagonistima receptora angiotenzina II od drugog tromjesečja trudnoće nadalje, preporučuje se ultrazvučni pregled bubrežne funkcije i lubanje.
English: If you take more Ifirmasta than you should If you accidentally take too many tablets, contact your doctor immediately.
Croatian: Ako slučajno uzmete previše tableta, odmah se obratite svom liječniku.
English: When Ifirmasta is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended.
Croatian: Oštećena funkcija bubrega i transplantacija bubrega Kada Ifirmastu uzimaju bolesnici s oštećenom funkcijom bubrega, preporučuje se periodički kontrolirati serumske razine kalija i kreatinina.
English: Blood and lymphatic system disorders: Not known:
Croatian: Poremećaji krvi i limfnog sustava Nepoznato:
English: The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive.
Croatian: Učinci irbesartana i tiazidnih diuretika na sniženje krvnog tlaka su aditivni.
English: - Uncommon (may affect up to 1 in 100 people): heart rate increased, flushing, cough, diarrhoea, indigestion/heartburn, sexual dysfunction (problems with sexual performance), chest pain.
Croatian: - Manje često (mogu se javiti u manje od 1 na 100 osoba): ubrzani otkucaji srca, crvenilo praćeno osjećajem vrućine, kašalj, proljev, probavni poremećaji/žgaravica, problemi sa seksualnom funkcijom, bol u prsima.
English: Hyperkalemia
Croatian: hiperkalijemija
English: Diabetes Mellitus (IRMA 2)” shows that irbesartan 300 mg delays progression to overt proteinuria in patients with microalbuminuria.
Croatian: Klinička studija «Učinak irbesartana na mikroalbuminuriju u hipertenzivnih bolesnika sa šećernom bolešću tipa 2 (IRMA 2)» pokazuje da 300 mg irbesartana odgađa progresiju izražene proteinurije u bolesnika s mikroalbuminurijom.
English: The decrease in blood pressure is dose-related for once a day doses with a tendency towards plateau at doses above 300 mg. Doses of 150-300 mg once daily lower supine or seated blood pressures at trough (i.e. 24 hours after dosing) by an average of 8-13/5-8 mm Hg (systolic/diastolic) greater than those associated with placebo.
Croatian: Doze od 150 do 300 mg jedanput na dan smanjuju krvni tlak u ležećem ili sjedećem položaju u vrijeme najniže koncentracije u krvi (to jest 24 sata nakon uzimanja doze) i to u prosjeku za 8-13/5-8 mmHg (sistolički/dijastolički) više od placeba.
English: Do not take Ifirmasta - if you are allergic to irbesartan or any of the other ingredients of this medicine (listed in section 6), - if you are more than 3 months pregnant.
Croatian: Nemojte uzimati Ifirmastu - ako ste alergični na irbesartan ili neki drugi sastojak ovog lijeka (naveden u dijelu 6), - ako ste trudni više od 3 mjeseca (preporučuje se, također, izbjegavati Ifirmastu u ranoj trudnoći - vidjeti dio o trudnoći), - ako imate šećernu bolest ili oštećenu bubrežnu funkciju i liječite se lijekom za snižavanje krvnog tlaka koji sadrži aliskiren.
English: The dose may later be increased to 300 mg (four tablets a day) once daily depending on blood pressure response.
Croatian: Doza se kasnije može povećati na 300 mg (četiri tablete na dan) jednom na dan, ovisno o vrijednostima krvnog tlaka.
English: The most likely manifestations of overdosage are expected to be hypotension and tachycardia; bradycardia might also occur from overdose.
Croatian: Najčešće očekivane manifestacije predoziranja su hipotenzija i tahikardija.
English: The dose may later be increased to 300 mg (two tablets a day) once daily depending on blood pressure response.
Croatian: Doza se kasnije može povećati na 300 mg (dvije tablete na dan) jednom na dan, ovisno o vrijednostima krvnog tlaka.
English: Ifirmasta 300 mg film-coated tablets 14 tablets: EU/1/08/480/013
Croatian: Ifirmasta 300 mg filmom obložene tablete 14 tableta: EU/1/08/480/013
English: Potassium supplements and potassium-sparing diuretics:
Croatian: Nadomjesci kalija i diuretici koji štede kalij:
English: The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).
Croatian: Primjena antagonista receptora angiotenzina II ne preporučuje se tijekom prvog tromjesečja trudnoće (vidjeti dio 4.4), a kontraindicirana je tijekom drugog i trećeg tromjesečja (vidjeti dijelove 4.3 i 4.4).
English: Ifirmasta 150 mg film-coated tablets 14 tablets: EU/1/08/480/007
Croatian: Ifirmasta 150 mg filmom obložene tablete 14 tableta: EU/1/08/480/007
English: In the female and black subgroups which represented 32% and 26% of the overall study population respectively, a renal benefit was not evident, although the confidence intervals do not exclude it. As for the secondary endpoint of fatal and non-fatal cardiovascular events, there was no difference among the three groups in the overall population, although an increased incidence of non-fatal MI was seen for women and a decreased incidence of non-fatal MI was seen in males in the irbesartan group versus the placebobased regimen.
Croatian: Za sekundarni ishod fatalnih i nefatalnih kardiovaskularnih događaja, u sveukupnoj ispitivanoj populaciji nije bilo razlika između tri skupine, iako je zabilježena povećana incidencija nefatalnog infarkta miokarda u žena i smanjena incidencija nefatalnog infarkta miokarda u muškaraca u skupini koja je primala irbesartan u odnosu na onu koja je primala placebo.
English: Excipient with known effect Ifirmasta 75 mg film-coated tablets Each film-coated tablet contains 4 mg castor oil.
Croatian: Pomoćna tvar s poznatim učinkom Ifirmasta 75 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 4 mg ricinusovog ulja.
English: What Ifirmasta looks like and contents of the pack Ifirmasta 75 mg film-coated tablets are: white, oval film-coated tablets.
Croatian: Kako Ifirmasta izgleda i sadržaj pakiranja Ifirmasta 75 mg filmom obložene tablete su: bijele, ovalne, filmom obložene tablete.
English: Ifirmasta 300 mg film-coated tablets Each film-coated tablet contains 16 mg castor oil.
Croatian: Ifirmasta 300 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 16 mg ricinusovog ulja.
English: Low-substituted Hydroxypropyl Cellulose (LH-21) Low-substituted Hydroxypropyl Cellulose (LH-11) Talc
Croatian: Jezgra tablete: manitol hidroksipropilceluloza hidroksipropilceluloza, nisko supstituirana (LH-21) hidroksipropilceluloza, nisko supstituirana (LH-11) talk makrogol 6000 ricinusovo ulje, hidrogenirano
English: Rreversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors.
Croatian: Tijekom istodobne primjene litija i inhibitora angiotenzin konvertirajućeg enzima zabilježen je reverzibilan porast koncentracije serumskog litija i njegove toksičnosti.
English: What Ifirmasta looks like and contents of the pack Ifirmasta 300 mg film-coated tablets are: white, oval film-coated tablets.
Croatian: Kako Ifirmasta izgleda i sadržaj pakiranja Ifirmasta 300 mg filmom obložene tablete su: bijele, ovalne, filmom obložene tablete.
English: Ifirmasta 75 mg film-coated tablets Each film-coated tablet contains 75 mg irbesartan (as hydrochloride).
Croatian: Ifirmasta 75 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 75 mg irbesartana (u obliku irbesartanklorida).
English: Studies have not been performed in patients with severe hepatic impairment.
Croatian: Nisu provođena ispitivanja u bolesnika s teškim oštećenjem funkcije jetre.
English: Ifirmasta 150 mg film-coated tablets Each film-coated tablet contains 8 mg castor oil.
Croatian: Ifirmasta 150 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 8 mg ricinusovog ulja.
English: Ifirmasta 75 mg film-coated tablets Irbesartan
Croatian: Ifirmasta 75 mg filmom obložene tablete irbesartan
English: What Ifirmasta looks like and contents of the pack Ifirmasta 150 mg film-coated tablets are: white, oval film-coated tablets.
Croatian: Kako Ifirmasta izgleda i sadržaj pakiranja Ifirmasta 150 mg filmom obložene tablete su: bijele, ovalne, filmom obložene tablete.
English: Ifirmasta 300 mg film-coated tablets Irbesartan
Croatian: Ifirmasta 300 mg filmom obložene tablete irbesartan
English: orthostatic hypotension* Uncommon: flushing
Croatian: ortostatska hipotenzija* Manje često: crvenilo praćeno osjećajem vrućine
English: Respiratory, thoracic and mediastinal disorders: Uncommon: cough
Croatian: Poremećaji dišnog sustava, prsišta i sredoprsja: Manje često: kašalj
English: Serum potassium levels are not significantly affected by irbesartan alone at the recommended doses.
Croatian: Pri preporučenim dozama irbesartan ne utječe značajno na razine serumskog kalija.
English: Ifirmasta 150 mg film-coated tablets Each film-coated tablet contains 150 mg irbesartan (as hydrochloride).
Croatian: Ifirmasta 150 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 150 mg irbesartana (u obliku irbesartanklorida).
English: Uncommon: may affect up to 1 in 100 people
Croatian: Često: mogu se javiti u manje od 1 na 10 osoba Manje često: mogu se javiti u manje od 1 na 100 osoba
English: Ifirmasta 300 mg film-coated tablets Each film-coated tablet contains 300 mg irbesartan (as hydrochloride).
Croatian: Ifirmasta 300 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 300 mg irbesartana (u obliku irbesartanklorida).
English: Ifirmasta 150 mg film-coated tablets are available in boxes of 14, 28, 30, 56, 84, 90 and 98 film-coated tablets in blisters and in boxes of 56 x 1 film-coated tablets in perforated unit dose blisters.
Croatian: Ifirmasta 150 mg filmom obložene tablete: dostupne u kutijama s 14, 28, 30, 56, 84, 90 i 98 filmom obloženih tableta u blisterima i kutijama s 56 x 1 filmom obloženih tableta u perforiranim blisterima djeljivim na jedinične doze.
English: Ifirmasta 150 mg film-coated tablets Irbesartan
Croatian: Ifirmasta 150 mg filmom obložene tablete irbesartan
English: Ifirmasta 75 mg film-coated tablets are available in boxes of 14, 28, 30, 56, 84, 90 and 98 film-coated tablets in blisters and in boxes of 56 x 1 film-coated tablets in perforated unit dose blisters.
Croatian: Ifirmasta 75 mg filmom obložene tablete dostupne u kutijama s 14, 28, 30, 56, 84, 90 i 98 filmom obloženih tableta u blisterima i kutijama s 56 x 1 filmom obloženih tableta u perforiranim blisterima djeljivim na jedinične doze.
English: Each film-coated tablet contains 75 mg irbesartan (as hydrochloride).
Croatian: Svaka filmom obložena tableta sadrži 75 mg irbesartana (u obliku irbesartanklorida).
English: Subgroups consisting of gender, race, age, duration of diabetes, baseline blood pressure, serum creatinine, and albumin excretion rate were assessed for treatment effect.
Croatian: Za učinak liječenja ocjenjivane su podskupine prema spolu, rasi, dobi, trajanju šećerne bolesti, početnom krvnom tlaku, serumskom kreatininu i izlučivanju albumina.U podskupinama žena i pripadnika crne rase, koji su činili 32% odnosno 26% ukupne populacije u studiji, nisu bili vidljivi povoljni učinci na bubrege, premda to intervali pouzdanosti nisu isključivali.